» Articles » PMID: 17539985

The Gastro-oesophageal Reflux Disease Impact Scale: a Patient Management Tool for Primary Care

Overview
Date 2007 Jun 2
PMID 17539985
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Symptoms of gastro-oesophageal reflux disease have a substantial impact on patients' everyday lives.

Aim: To develop and test a short questionnaire to aid patient-doctor communication.

Methods: The Gastro-oesophageal Reflux Disease Impact Scale was developed from a systematic literature review, focus groups of patients and primary care physicians, and patient cognitive interviews. A psychometric validation study was conducted based on two consultations in new (n = 100) or chronic (n = 105) gastro-oesophageal reflux disease patients.

Results: The Gastro-oesophageal Reflux Disease Impact Scale demonstrated internal consistency (Cronbach's alpha ranged from 0.68 to 0.82), reproducibility (intraclass correlation coefficient in stable patients ranged from 0.61 to 0.72) and construct validity (Spearman correlations with Quality of Life in Reflux and Dyspepsia instrument and Reflux Disease Questionnaire: 0.5-0.8 in both patient groups). Effect sizes in new and chronic gastro-oesophageal reflux disease patients ranged from 0.9 to 1.5 and 0.32 to 0.42, respectively. Doctors reported altering their treatment decision based on information provided by the Gastro-oesophageal Reflux Disease Impact Scale in 35% of patients, and 77% of doctors found it to be useful.

Conclusions: The Gastro-oesophageal Reflux Disease Impact Scale demonstrated good psychometric properties in newly diagnosed gastro-oesophageal reflux disease patients and those already receiving treatment. This simple communication tool is a useful aid for managing primary care patients with gastro-oesophageal reflux disease.

Citing Articles

Patient journey in gastroesophageal reflux disease: real-world perspectives from Italian gastroenterologists, primary care physicians, and ENT specialists.

Pasta A, Pelizzaro F, Marabotto E, Calabrese F, Formisano E, Djahandideh Sheijani S Therap Adv Gastroenterol. 2024; 17:17562848241239590.

PMID: 38524789 PMC: 10960349. DOI: 10.1177/17562848241239590.


The Effect of Dexlansoprazole on Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.

Nunes G, Silveira T, Marciano J, Reis-Prado A, Ferrisse T, Dos Anjos E Int J Mol Sci. 2024; 25(2).

PMID: 38279248 PMC: 10816097. DOI: 10.3390/ijms25021247.


A comparison between a gastroesophageal reflux disease questionnaire-based algorithm and multichannel intraluminal impedance-pH monitoring for the treatment of gastroesophageal reflux-induced chronic cough.

Li W, Zhang T, Gu W, Shi W, Wang S, Zhu Y Ther Adv Respir Dis. 2024; 18:17534666231220817.

PMID: 38183243 PMC: 10771753. DOI: 10.1177/17534666231220817.


Guidelines for best practices in monitoring established coeliac disease in adult patients.

Elli L, Leffler D, Cellier C, Lebwohl B, Ciacci C, Schumann M Nat Rev Gastroenterol Hepatol. 2023; 21(3):198-215.

PMID: 38110546 DOI: 10.1038/s41575-023-00872-2.


The Prevalence of Gastroesophageal Reflux Disease in Azerbaijan: A Population-Based Cross-sectional Study.

Aghayeva S, Katzka D, Afandiyeva N, Bor S, Babayeva G, Hidayatov A Turk J Gastroenterol. 2023; 34(11):1134-1142.

PMID: 37768307 PMC: 10724836. DOI: 10.5152/tjg.2023.211042.